Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Canadian rTMS Treatment and Biomarker Network in Depression (CARTBIND) Trial

Project Overview

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for patients with depression who have not responded to antidepressant medications. rTMS involves stimulating the brain with a series of magnetic pulses delivered through a hand-held magnetic coil. Treatment duration is about 40 min and about 8-10 treatments per day can be administered. Recent studies have shown that a new type of rTMS – called intermittent theta-burst stimulation (iTBS) – can also be effective in treating depression. iTBS takes only 3 minutes to administer. For this proposal, Zafiris Daskalakis and his team are conducting a clinical trial comparing standard rTMS to iTBS in 294 patients with medication resistant depression over a course of 20 treatment sessions. Half will receive conventional rTMS treatment and the other half will receive iTBS. To better understand how rTMS works they are also evaluating changes in brain biology that occur with rTMS treatment. Understanding brain biology changes will help to better predict which patients will or will not respond to rTMS treatment. The teams preliminary work thus far demonstrates that iTBS works as well as standard rTMS in depression. Their preliminary work of imaging brain biology also suggests that they can effectively identify which patients respond best to rTMS treatment. If successful, this project will demonstrate a method for increasing rTMS clinic treatment capacities 8-10 fold. This 8-10-fold increase will be a crucial step forward in improving access to rTMS for all Canadians. Overall, this proposal will have ‘real-world’ impact by improving the efficiency of rTMS – one of the few established treatments in medication resistant depression – and by producing more personalized treatment approaches.

Principal Investigator

Zafiris Daskalakis , Centre for Addiction and Mental Health

Team Members

Fidel Vila-Rodriguez, University of British Columbia

Aristotle Voineskos, Centre for Addiction and Mental Health

Sidney H. Kennedy, University Health Network

Raymond Lam, University of British Columbia

Jonathan Downar, Toronto Western Research Institute, University of Toronto

Daniel Blumberger, Centre for Addiction and Mental Health

Tarek Rajji, Centre for Addiction and Mental Health

Gustavo Turecki, Douglas Hospital Research Centre

Christopher Honey, University of Toronto

Partners and Donors

University of British Columbia

Toronto General & Western Hospital Foundation

Centre for Addiction and Mental Health (CAMH)

Project Complete

Canadian rTMS Treatment and Biomarker Network in Depression (CARTBIND) Trial

  • Grant Type

    Team grants

  • Area of research

    Mental Health

  • Disease Area

    Mental illness

  • Competition

    2014 MIRI Team Grants

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,387,500

  • Health Canada Contribution

    $693,750

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co

  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds
Project Directory
Donate Now